New medicine funded to combat multi-resistant infections

Published: Fri 31 Oct 2014 10:26 AM
Embargoed to 0600 Friday 31 October
Media release
New medicine funded to combat multi-resistant infections
New Zealand hospitals are about to strengthen their defences against multi-resistant bacterial infections with the funding of a new antibiotic.
From 1 November PHARMAC will add ceftaroline fosamil to the list of medicines funded in DHB hospitals. Ceftaroline is a fifth-generation cephalosporin, an updated version of a long line of effective anti-bacterials. It will be particularly targeted at people exposed to multi-resistant strains of bacterial infections, more commonly referred to as `superbugs’.
Deputy Medical Director Dr Dilky Rasiah says the listing of ceftaroline is timely, given the high level of concern internationally around growing bacterial resistance to antibiotics.
Dr Rasiah says ceftaroline will be preserved as a `last-line’ defence against multi-resistant organisms, to help protect its usefulness.
“Multi-resistant bacteria are now a reality, so it’s important that we have more tools at our disposal to deal with them,” she says. “We continue to have an effective range of antibiotics, but every so often we encounter a strain or type of bacteria that requires several different types of antibiotic to treat it, or people can find it hard to take other antibiotics.”
“It’s a bit like links in a chain, and what we are doing with this decision is adding another link to that chain.”
“As well as making funding available, part of PHARMAC’s role is in antimicrobial stewardship – working alongside other agencies and health professionals to ensure that these important medicines continue to be effective for the future.”
“That is why we are being very careful with how this new option will be targeted.”
In New Zealand, rates of multi drug-resistant infections are monitored through ESR. Data on rates of infection in New Zealand are published on the ESR website.
ESR Clinical Microbiologist Dr Deborah Williamson says it is important New Zealand confronts the challenge of antimicrobial resistance, one of the biggest man-made public health threats of modern times.
"New Zealand is fortunate to have a coordinated programme of antimicrobial resistance surveillance that is based at ESR.
"We have recently been involved in antimicrobial susceptibility testing of ceftaroline in New Zealand, and believe it will be a valuable new drug," Dr Williamson says.

Next in Lifestyle

Endeavour arrives at Tūranganui-a-Kiwa as part of Tuia 250
NZ Improv Fest Turns It Up To Eleven
By: NZ Improv Festival
$12 million investment in stimulating content for tamariki
By: NZ On Air
Author Jack Lasenby remembered as master storyteller
Tuia 250 Voyage flotilla launches with tribute
By: New Zealand Government
Whangaparāoa iwi commemorate arrival of waka tīpuna
By: New Zealand Government
Tuia 250 - Te Pōwhiri - Te Whanganui o Hei / Mercury Bay
By: Tuia 250
HMB Endeavour replica arrives in NZ to join Tuia 250 Voyage
By: Tuia 250
Tuia Mātauranga Roadshow kicks off
By: Ministry of Education
UK govt's expression of regret to Gisborne iwi
Release of critical book on Cook Commemorations
By: Kia Mau
Endeavour was a military invasion
By: Auckland Peace Action
Extinction Rebellion Aotearoa launch decolonisation action
By: Extinction Rebellion
More laugh therapy ordered for New Zealanders
By: NZ On Air
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media